Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Inclusion Criteria:

- ECOG ≤ 1

- Willing to undergo tumor biopsies from injected and distal lesions

- Must have two biopsy accessible lesions:

- * one lesion must be ≥10 mm and <100 mm in longest diameter, accessible for
repeated intratumoral (IT) injection and accessible for baseline and on-treatment
biopsies.

- a second (distal) lesion must be accessible for baseline and on-treatment
biopsy and must be distinct from the injected lesion.

- tumors encasing major vascular structures (i.e., carotid artery or tumors
close to other vital organs), are not considered appropriate

Exclusion Criteria:

- Patients who require local palliative measures such as XRT or surgery

- Symptomatic or untreated leptomeningeal disease.

- Presence of symptomatic central nervous system (CNS) metastases

- Impaired cardiac function or clinically significant cardiac disease

- Active autoimmune disease or a documented history of autoimmune disease, except
vitiligo or resolved childhood asthma/atopy.

- Active infection requiring systemic antibiotic therapy.

- Known history of Human Immunodeficiency Virus (HIV) infection.

- Active Epstein-Barr virus (EBV), hepatitis B virus (HBV) or hepatitis C virus (HCV)

- Malignant disease, other than that being treated in this study.